Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Receivables - Accured (2022 - 2023)

Rani Therapeutics Holdings has reported Receivables - Accured over the past 2 years, most recently at $200000.0 for Q4 2023.

  • Quarterly results put Receivables - Accured at $200000.0 for Q4 2023, changed 0.0% from a year ago — trailing twelve months through Dec 2023 was $200000.0 (changed 0.0% YoY), and the annual figure for FY2023 was $200000.0, changed 0.0%.
  • Receivables - Accured for Q4 2023 was $200000.0 at Rani Therapeutics Holdings, roughly flat from $200000.0 in the prior quarter.
  • Over the last five years, Receivables - Accured for RANI hit a ceiling of $200000.0 in Q4 2022 and a floor of $100000.0 in Q1 2023.